TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants

Current Infectious Disease Reports

Volumn 12, Issue 1, 2010, Pages 4-12

  Higgins, Sarah C ^a   Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Adjuvant; C type lectin receptor; Immune modulator; Infection; NLR; TLR; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; AMPLIGEN; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; FLAGELLIN; FREUND ADJUVANT; HEPATITIS B VACCINE; IMIQUIMOD; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; LECTIN RECEPTOR; LIPID EMULSION; LIPOPOLYSACCHARIDE; LIPOSOME; MALARIA VACCINE; MURABUTIDE; MURAMYL DIPEPTIDE; MURAMYL TRIPEPTIDE DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; POLYPEPTIDE; RECEPTOR PROTEIN; RETINOIC ACID INDUCIBLE GENE 1 LIKE RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; WART VIRUS VACCINE;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; IMMUNITY; INFECTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; WEGENER GRANULOMATOSIS;

EID: 77249138709     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0080-9     Document Type: Review

References (63)

1. CA Janeway Jr 1989 Approaching the asymptote? Evolution and revolution in immunology Cold Spring Harb Symp Quant Biol 54 Pt 1 1 13 2700931 1:CAS:528:DyaK3cXkslGqtrY%3D
2. CA Janeway Jr R Medzhitov 2002 Innate immune recognition Annu Rev Immunol 20 197 216 10.1146/annurev.immunol.20.083001.084359 11861602 1:CAS:528:DC%2BD38XjtlWgt7Y%3D (Pubitemid 34293424)
3. SC Higgins AG Jarnicki EC Lavelle KH Mills 2006 TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells J Immunol 177 7980 7989 17114471 1:CAS:528: DC%2BD28Xht1WrsLvM
4. T Querec S Bennouna S Alkan, et al. 2006 Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity J Exp Med 203 413 424 10.1084/jem.20051720 16461338 (Pubitemid 43290850)
5. R Medzhitov 2001 Toll-like receptors and innate immunity Nat Rev Immunol 1 135 145 10.1038/35100529 11905821 1:CAS:528:DC%2BD38XlvF2qu74%3D
6. RM Condie SJ Zak RA Good 1955 Effect of meningococcal endotoxin on the immune response Proc Soc Exp Biol Med 90 355 360 13273447 1:CAS:528: DyaG28XhslWnsg%3D%3D
7. JR Baldridge RT Crane 1999 Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines Methods 19 103 107 10.1006/meth.1999.0834 10525445 1:CAS:528:DyaK1MXms1CqtrY%3D (Pubitemid 29497759)
8. JM Blander R Medzhitov 2006 Toll-dependent selection of microbial antigens for presentation by dendritic cells Nature 440 808 812 10.1038/nature04596 16489357 1:CAS:528:DC%2BD28XjtFKjsLo%3D
9. KA Bojang F Olodude M Pinder, et al. 2005 Safety and immunogenicty of RTS, S/AS02A candidate malaria vaccine in Gambian children Vaccine 23 4148 4157 10.1016/j.vaccine.2005.03.019 15964483 1:CAS:528:DC%2BD2MXlt1Kjtrs%3D (Pubitemid 40814590)
10. PA Bovier T Farinelli L Loutan 2005 Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine Vaccine 23 2424 2429 10.1016/j.vaccine.2004.11.024 15752828 1:CAS:528:DC%2BD2MXitVCgs74%3D (Pubitemid 40332514)
11. SH Kaufmann 2007 Tuberculosis and AIDS-a devilish liaison Drug Discov Today 12 21-22 891 893 17993405
12. S McCormack A Tilzey A Carmichael, et al. 2000 A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320 Vaccine 18 1166 1177 10.1016/S0264-410X(99)00388-6 10649617 1:CAS:528:DC%2BD3cXnsFylsQ%3D%3D (Pubitemid 30001830)
13. T Verstraeten D Descamps MP David, et al. 2008 Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines Vaccine 26 6630 6638 10.1016/j.vaccine.2008.09.049 18845199 1:CAS:528:DC%2BD1MXhsVanu74%3D
14. DT O'Hagan E De Gregorio 2009 The path to a successful vaccine adjuvant-'the long and winding road' Drug Discov Today 14 11-12 541 551 10.1016/j.drudis.2009.02.009 19508916 1:CAS:528:DC%2BD1MXmvFajur0%3D
15. BC Baudner V Ronconi D Casini, et al. 2009 MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020) Pharm Res 26 1477 1485 10.1007/s11095-009-9859-5 19255727 1:CAS:528:DC%2BD1MXisFWns7g%3D
16. M Dupuis TJ Murphy D Higgins, et al. 1998 Dendritic cells internalize vaccine adjuvant after intramuscular injection Cell Immunol 186 18 27 10.1006/cimm.1998.1283 9637761 1:STN:280:DyaK1czhtVOqug%3D%3D (Pubitemid 28285344)
17. F Mosca E Tritto A Muzzi, et al. 2008 Molecular and cellular signatures of human vaccine adjuvants Proc Natl Acad Sci USA 105 10501 10506 10.1073/pnas.0804699105 18650390
18. T Ichinohe S Tamura A Kawaguchi, et al. 2007 Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine J Infect Dis 196 1313 1320 10.1086/521304 17922395 1:CAS:528:DC%2BD2sXhtlOmtbnP
19. H Kumar S Koyama KJ Ishii, et al. 2008 Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses J Immunol 180 683 687 18178804 1:CAS:528: DC%2BD1cXhsVyjsA%3D%3D
20. RJ Suhadolnik NL Reichenbach P Hitzges, et al. 1994 Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome Clin Infect Dis 18 Suppl 1 S96 S104 8148461
21. JT Bates AN Honko AH Graff, et al. 2008 Mucosal adjuvant activity of flagellin in aged mice Mech Ageing Dev 129 271 281 10.1016/j.mad.2008.01.009 18367233 1:CAS:528:DC%2BD1cXksVamsLw%3D
22. AN Honko SB Mizel 2004 Mucosal administration of flagellin induces innate immunity in the mouse lung Infect Immun 72 6676 6679 10.1128/IAI.72.11.6676- 6679.2004 15501801 1:CAS:528:DC%2BD2cXpsFekuro%3D (Pubitemid 39425451)
23. SJ McSorley BD Ehst Y Yu AT Gewirtz 2002 Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo J Immunol 169 3914 3919 12244190 1:CAS:528:DC%2BD38XnsFeltb0%3D
24. G Doring C Meisner M Stern 2007 A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients Proc Natl Acad Sci U S A 104 11020 11025 10.1073/pnas.0702403104 17585011 1:CAS:528:DC%2BD2sXnsV2ks7w%3D (Pubitemid 47175219)
25. F Heil H Hemmi H Hochrein, et al. 2004 Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Science 303 1526 1529 10.1126/science.1093620 14976262 1:CAS:528:DC%2BD2cXhslCgsLc%3D (Pubitemid 38314424)
26. KB Gorden KS Gorski SJ Gibson, et al. 2005 Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8 J Immunol 174 1259 1268 15661881 1:CAS:528:DC%2BD2MXlsFyhsQ%3D%3D
27. H Hemmi T Kaisho O Takeuchi, et al. 2002 Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat Immunol 3 196 200 10.1038/ni758 11812998 1:CAS:528:DC%2BD38XhtVygurc%3D (Pubitemid 34141451)
28. DM Klinman H Xie SF Little, et al. 2004 CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques Vaccine 22 21-22 2881 2886 10.1016/j.vaccine.2003.12.020 15246624 1:CAS:528:DC%2BD2cXls1WktLw%3D (Pubitemid 38900667)
29. C Schmidt 2007 Clinical setbacks for toll-like receptor 9 agonists in cancer Nat Biotechnol 25 825 826 10.1038/nbt0807-825 17687345 1:CAS:528:DC%2BD2sXos12nsb8%3D (Pubitemid 47236890)
30. C Schubert 2009 Boosting our best shot. Nat Med 15 984 988 1:CAS:528:DC%2BD1MXhtV2gsbrP
31. H Conroy NA Marshall KH Mills 2008 TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours Oncogene 27 168 180 10.1038/sj.onc.1210910 18176598 1:CAS:528:DC%2BD1cXitl2hsQ%3D%3D
32. • Jarnicki AG, Conroy H, Brereton C, et al.: Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008, 180:3797-3806. This article illustrates the limitations of TLR agonists as adjuvants and how they can be made more effective by modulating downstream signaling pathways.
33. AL Gavin K Hoebe B Duong, et al. 2006 Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling Science 314 1936 1938 10.1126/science.1135299 17185603 1:CAS:528:DC%2BD28Xhtlemt7fN (Pubitemid 46026117)
34. CB Lopez B Moltedo L Alexopoulou, et al. 2004 TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses J Immunol 173 6882 6889 15557183 1:CAS:528:DC%2BD2cXhtVShsbzE
35. CJ Sanders L Franchi F Yarovinsky, et al. 2009 Induction of adaptive immunity by flagellin does not require robust activation of innate immunity Eur J Immunol 39 359 371 10.1002/eji.200838804 19152336 1:CAS:528: DC%2BD1MXitlCqu7w%3D
36. EA Miao CM Alpuche-Aranda M Dors, et al. 2006 Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf Nat Immunol 7 569 575 10.1038/ni1344 16648853 1:CAS:528:DC%2BD28Xksleksbs%3D (Pubitemid 43797337)
37. H Kato S Sato M Yoneyama, et al. 2005 Cell type-specific involvement of RIG-I in antiviral response Immunity 23 19 28 10.1016/j.immuni.2005.04.010 16039576 1:CAS:528:DC%2BD2MXnsVeltrs%3D (Pubitemid 41019654)
38. T Kawai K Takahashi S Sato, et al. 2005 IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction Nat Immunol 6 981 988 10.1038/ni1243 16127453 1:CAS:528:DC%2BD2MXhtVajs7fJ (Pubitemid 41486182)
39. • Kobiyama K, Takeshita F, Ishii KJ, et al.: A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant. J Immunol 2009, 182:1593-1601. These authors showed that a polypeptide corresponding to an intracellular signaling molecule in the RIG-1 pathway could enhanced immune responses in vivo and therefore had potential as an adjuvant.
40. A Adam R Ciorbaru JF Petit E Lederer 1972 Isolation and properties of a macromolecular, water-soluble, immuno-adjuvant fraction from the cell wall of Mycobacterium smegmatis Proc Natl Acad Sci U S A 69 851 854 10.1073/pnas.69.4. 851 4502937 1:CAS:528:DyaE38XktFOqsr0%3D
41. JG Magalhaes JH Fritz L Le Bourhis, et al. 2008 Nod2-dependent Th2 polarization of antigen-specific immunity J Immunol 181 7925 7935 19017983 1:CAS:528:DC%2BD1cXhtl2gsLzM
42. W Keitel R Couch N Bond, et al. 1993 Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant Vaccine 11 909 913 10.1016/0264-410X(93) 90376-9 8212835 1:STN:280:DyaK2c%2FisF2jsw%3D%3D
43. L Franchi T Eigenbrod R Munoz-Planillo G Nunez 2009 The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis Nat Immunol 10 241 247 10.1038/ni.1703 19221555 1:CAS:528:DC%2BD1MXhvFKjtLo%3D
44. MJ Staruch DD Wood 1983 The adjuvanticity of interleukin 1 in vivo J Immunol 130 2191 2194 6601146 1:CAS:528:DyaL3sXhvFKiu7Y%3D
45. TD Kanneganti M Body-Malapel A Amer, et al. 2006 Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA J Biol Chem 281 36560 36568 10.1074/jbc.M607594200 17008311 1:CAS:528:DC%2BD28Xht1eltrvO (Pubitemid 46042123)
46. F Martinon J Tschopp 2007 Inflammatory caspases and inflammasomes: master switches of inflammation Cell Death Differ 14 10 22 10.1038/sj.cdd.4402038 16977329 1:CAS:528:DC%2BD28XhtlSqur%2FJ (Pubitemid 44911890)
47. 2-generation by xanthine oxidase of pathogenesis of influenza virus infection in mice J Clin Invest 85 739 745 10.1172/JCI114499 2155924 1:CAS:528:DyaK3cXhslKgsr0%3D
48. Y Shi JE Evans KL Rock 2003 Molecular identification of a danger signal that alerts the immune system to dying cells Nature 425 516 521 10.1038/nature01991 14520412 1:CAS:528:DC%2BD3sXnslSis7g%3D (Pubitemid 37237047)
49. V Hornung F Bauernfeind A Halle, et al. 2008 Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization Nat Immunol 9 847 856 10.1038/ni.1631 18604214 1:CAS:528:DC%2BD1cXoslCmurs%3D
50. • Eisenbarth SC, Colegio OR, O'Connor W, et al.: Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126. This article provided the first evidence that the mechanism of action of alum may be mediated through activation of innate immunity (Editor: make this two star reference).
51. M Kool V Petrilli T De Smedt, et al. 2008 Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome J Immunol 181 3755 3759 18768827 1:CAS:528:DC%2BD1cXhtVKntLzK
52. H Li SB Willingham JP Ting F Re 2008 Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3 J Immunol 181 17 21 18566365 1:CAS:528:DC%2BD1cXnsVGjsLk%3D
53. • Sharp FA, Ruane D, Claass B, et al.: Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009, 106:870-875. This article shows that biodegradable microparticles have adjuvant as well as vaccine delivery properties, and that this activity is mediated through activation of the inflammasome.
54. TB Geijtenbeek SI Gringhuis 2009 Signalling through C-type lectin receptors: shaping immune responses Nat Rev Immunol 9 465 479 10.1038/nri2569 19521399 1:CAS:528:DC%2BD1MXntFCgurc%3D
55. K Werninghaus A Babiak O Gross, et al. 2009 Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation J Exp Med 206 89 97 10.1084/jem.20081445 19139169 1:CAS:528:DC%2BD1MXhtVOhtbc%3D
56. RE Geisel K Sakamoto DG Russell ER Rhoades 2005 In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette-Guerin is due principally to trehalose mycolates J Immunol 174 5007 5015 15814731 1:CAS:528:DC%2BD2MXivFKhsrw%3D
57. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge Nat Immunol 8 369 377 10.1038/ni1449 17351619 1:CAS:528:DC%2BD2sXjt1SqsLY%3D (Pubitemid 46745412)
58. KM Lima SA Santos VM Lima, et al. 2003 Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis Gene Ther 10 678 685 10.1038/sj.gt.3301908 12692596 1:CAS:528:DC%2BD3sXivVWktbg%3D (Pubitemid 36553613)
59. J Davidsen I Rosenkrands D Christensen, et al. 2005 Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses Biochim Biophys Acta 1718 1-2 22 31 16321607 1:CAS:528:DC%2BD2MXht1OltLvJ
60. L Holten-Andersen TM Doherty KS Korsholm P Andersen 2004 Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines Infect Immun 72 1608 1617 10.1128/IAI.72.3.1608-1617.2004 14977968 1:CAS:528:DC%2BD2cXhvVCgsr4%3D (Pubitemid 38263784)
61. S LeibundGut-Landmann O Gross MJ Robinson, et al. 2007 Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17 Nat Immunol 8 630 638 10.1038/ni1460 17450144 1:CAS:528:DC%2BD2sXlsVSrs78%3D (Pubitemid 46785127)
62. G Napolitani A Rinaldi F Bertoni, et al. 2005 Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells Nat Immunol 6 769 776 10.1038/ni1223 15995707 1:CAS:528:DC%2BD2MXmtlSisLs%3D (Pubitemid 43090462)
63. JH Fritz SE Girardin C Fitting, et al. 2005 Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists Eur J Immunol 35 2459 2470 10.1002/eji.200526286 16021602 1:CAS:528:DC%2BD2MXps1Gmur4%3D (Pubitemid 41179767)